NTRB
Nutriband Inc.
Biotechnology
Market Cap$46M
5Y Perf.-29.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NTRB vs CLRB
Revenue, margins, valuation, and 5-year total return — side by side.
CLRB
Cellectar Biosciences, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-98.7%
NTRB vs CLRB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NTRB | CLRB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $46M | $14M |
| Revenue (TTM) | $2M | $0.00 |
| Net Income (TTM) | $-8M | $-22M |
| Gross Margin | 24.9% | — |
| Operating Margin | -408.4% | — |
| Total Debt | $210K | $410K |
| Cash & Equiv. | $5M | $13M |
NTRB vs CLRB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NTRB
CLRB
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Nutriband Inc. (NTRB) | 100 | 70.6 | -29.4% |
| Cellectar Bioscienc… (CLRB) | 100 | 1.3 | -98.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NTRB vs CLRB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NTRB leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Cellectar Biosciences, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
NTRB
Nutriband Inc.
The Income Pick
NTRB carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.20
- -34.0% 10Y total return vs CLRB's -99.9%
- Lower volatility, beta 1.20, Low D/E 3.1%, current ratio 6.36x
Best for: income & stability and long-term compounding
CLRB
Cellectar Biosciences, Inc.
The Growth Play
CLRB is the clearest fit if your priority is growth exposure.
- EPS growth 80.1%
- 51.3% revenue growth vs NTRB's -4.8%
- 2.9% margin vs NTRB's -404.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CLRB | 51.3% revenue growth vs NTRB's -4.8% |
| Quality / Margins | CLRB | 2.9% margin vs NTRB's -404.1% |
| Stability / Safety | NTRB | Beta 1.20 vs CLRB's 1.76, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NTRB | -34.4% vs CLRB's -55.0% |
| Efficiency (ROA) | NTRB | -101.9% ROA vs CLRB's -146.9% |
NTRB vs CLRB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNTRBLAGGINGCLRB
CLRBCellectar Biosciences…
0leads
NTRBNutriband Inc.
4leads
6 Total Categories
CATEGORYLEADERvs CLRBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NTRB1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NTRB6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRB5/6
Risk & VolatilityBeta, volatility, and downside exposure
NTRB2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NTRB leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NTRB and CLRB operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | NTRBNutriband Inc. | CLRBCellectar Bioscie… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$23M |
| Net IncomeAfter-tax profit | -$8M | -$22M |
| Free Cash FlowCash after capex | -$5M | -$23M |
| Gross MarginGross profit ÷ Revenue | +24.9% | — |
| Operating MarginEBIT ÷ Revenue | -4.1% | — |
| Net MarginNet income ÷ Revenue | -4.0% | — |
| FCF MarginFCF ÷ Revenue | -2.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -37.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +84.4% | +25.6% |
NTRB leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NTRB and CLRB each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NTRBNutriband Inc. | CLRBCellectar Bioscie… |
|---|---|---|
| Market CapShares × price | $46M | $14M |
| Enterprise ValueMkt cap + debt − cash | $42M | $1M |
| Trailing P/EPrice ÷ TTM EPS | -1.47x | -0.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 22.66x | — |
| Price / BookPrice ÷ Book value/share | 6.61x | 0.87x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NTRB and CLRB each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NTRB leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
NTRB delivers a -118.3% return on equity — every $100 of shareholder capital generates $-118 in annual profit, vs $-2 for CLRB. NTRB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to CLRB's 0.04x. On the Piotroski fundamental quality scale (0–9), NTRB scores 3/9 vs CLRB's 2/9, reflecting mixed financial health.
| Metric | NTRBNutriband Inc. | CLRBCellectar Bioscie… |
|---|---|---|
| ROE (TTM)Return on equity | -118.3% | -2.5% |
| ROA (TTM)Return on assets | -101.9% | -146.9% |
| ROICReturn on invested capital | -2.7% | — |
| ROCEReturn on capital employed | -125.5% | -174.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.03x | 0.04x |
| Net DebtTotal debt minus cash | -$4M | -$13M |
| Cash & Equiv.Liquid assets | $5M | $13M |
| Total DebtShort + long-term debt | $209,629 | $409,586 |
| Interest CoverageEBIT ÷ Interest expense | -369.11x | — |
NTRB leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
NTRB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRB five years ago would be worth $6,603 today (with dividends reinvested), compared to $81 for CLRB. Over the past 12 months, NTRB leads with a -34.4% total return vs CLRB's -55.0%. The 3-year compound annual growth rate (CAGR) favors NTRB at 3.5% vs CLRB's -57.7% — a key indicator of consistent wealth creation.
| Metric | NTRBNutriband Inc. | CLRBCellectar Bioscie… |
|---|---|---|
| YTD ReturnYear-to-date | -14.4% | -4.9% |
| 1-Year ReturnPast 12 months | -34.4% | -55.0% |
| 3-Year ReturnCumulative with dividends | +10.8% | -92.4% |
| 5-Year ReturnCumulative with dividends | -34.0% | -99.2% |
| 10-Year ReturnCumulative with dividends | -34.0% | -99.9% |
| CAGR (3Y)Annualised 3-year return | +3.5% | -57.7% |
NTRB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
NTRB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NTRB is the less volatile stock with a 1.20 beta — it tends to amplify market swings less than CLRB's 1.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NTRB currently trades 32.4% from its 52-week high vs CLRB's 16.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NTRBNutriband Inc. | CLRBCellectar Bioscie… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.20x | 1.76x |
| 52-Week HighHighest price in past year | $11.68 | $20.59 |
| 52-Week LowLowest price in past year | $3.42 | $2.43 |
| % of 52W HighCurrent price vs 52-week peak | +32.4% | +16.0% |
| RSI (14)Momentum oscillator 0–100 | 50.8 | 71.7 |
| Avg Volume (50D)Average daily shares traded | 11K | 1.2M |
NTRB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NTRBNutriband Inc. | CLRBCellectar Bioscie… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NTRB leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallNutriband Inc. (NTRB)Leads 4 of 6 categories
Loading custom metrics...
NTRB vs CLRB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NTRB or CLRB?
Over the past 5 years, Nutriband Inc.
(NTRB) delivered a total return of -34. 0%, compared to -99. 2% for Cellectar Biosciences, Inc. (CLRB). Over 10 years, the gap is even starker: NTRB returned -34. 0% versus CLRB's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NTRB or CLRB?
By beta (market sensitivity over 5 years), Nutriband Inc.
(NTRB) is the lower-risk stock at 1. 20β versus Cellectar Biosciences, Inc. 's 1. 76β — meaning CLRB is approximately 46% more volatile than NTRB relative to the S&P 500. On balance sheet safety, Nutriband Inc. (NTRB) carries a lower debt/equity ratio of 3% versus 4% for Cellectar Biosciences, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — NTRB or CLRB?
On earnings-per-share growth, the picture is similar: Cellectar Biosciences, Inc.
grew EPS 80. 1% year-over-year, compared to -160. 6% for Nutriband Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NTRB or CLRB?
Cellectar Biosciences, Inc.
(CLRB) is the more profitable company, earning 0. 0% net margin versus -404. 1% for Nutriband Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CLRB leads at 0. 0% versus -408. 4% for NTRB. At the gross margin level — before operating expenses — NTRB leads at 25. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NTRB or CLRB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NTRB or CLRB better for a retirement portfolio?
For long-horizon retirement investors, Nutriband Inc.
(NTRB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). Cellectar Biosciences, Inc. (CLRB) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRB: -34. 0%, CLRB: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NTRB and CLRB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.